Loading...
*  Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia - Full...
Neoplasms. Multiple Myeloma. Neoplasms, Plasma Cell. Myelodysplastic Syndromes. Preleukemia. Myeloproliferative Disorders. ... Neoplasms by Histologic Type. Lymphoproliferative Disorders. Lymphatic Diseases. Immunoproliferative Disorders. Immune System ... Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia. The ... Hematologic Diseases. Hemorrhagic Disorders. Bone Marrow Diseases. Precancerous Conditions. Lung Diseases, Interstitial. ...
  https://clinicaltrials.gov/ct2/show/NCT00008164
*  Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant...
Neoplasms, Plasma Cell. Myelodysplastic Syndromes. Preleukemia. Plasmacytoma. Neoplasms by Histologic Type. Neoplasms. ... Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Biological: donor lymphocytes ... RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that ... Hematologic relapse, as evidenced by , 20% blasts in bone marrow or soft tissue recurrence ...
  https://clinicaltrials.gov/ct2/show/NCT00534118?term=00534118&rank=1
*  A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. - Full Text View - ClinicalTrials.gov
Neoplasms. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Hematologic Neoplasms. Leukemia, Myeloid. Leukemia. Neoplasms by ... A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.. This study has been completed. ... administered as monotherapy in patients with hematologic neoplasms. A first cohort of patients will receive the starting dose ...
  https://clinicaltrials.gov/ct2/show/NCT00623870
*  Learn: Hematologic Neoplasms (by mrezadabiri) - Memorize.com - Remember and Understand
Learn Hematologic Neoplasms facts using a simple interactive process (flashcard, matching, or multiple choice). Finally a ...
  http://memorize.com/hematologic-neoplasms/mrezadabiri
*  Bone Marrow Synoptic Reporting for… | College of American Pathologists
The evidence-based guideline "Bone Marrow Synoptic Reporting for Hematologic Neoplasms" provides a framework for a synoptic ... includes nine statements to assist pathologists in producing complete and clear synoptic reports for hematologic neoplasms. The ...
  https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/bone-marrow-synoptic-reporting-for-hematologic-neoplasms
*  Compound Report Card
Hematologic Neoplasms. D019337. EFO:0001642. lymphoid neoplasm. 1. ClinicalTrials. Graft vs Host Disease. D006086. EFO:0004599 ...
  https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL416
*  Compound Report Card
Hematologic Neoplasms. D019337. EFO:0001642. lymphoid neoplasm. 2. ClinicalTrials. Leukemia, Lymphocytic, Chronic, B-Cell. ... Neoplasms. D009369. EFO:0000616. neoplasm. 4. ATC. Scleroderma, Systemic. D012595. EFO:0000717. systemic scleroderma. 2. ... Colonic Neoplasms. D003110. EFO:0004288. colonic neoplasm. 2. ClinicalTrials. Dermatomyositis. D003882. EFO:0000557. juvenile ... Breast Neoplasms. D001943. EFO:0003869. breast neoplasm. 2. ClinicalTrials. Diabetic Neuropathies. D003929. EFO:1000783. ...
  https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201576
*  Search of: cook children's - List Results - ClinicalTrials.gov
Hematologic Neoplasms. Observational. *Center for International Blood and Marrow Transplant Research. *National Marrow Donor ... Incidence of malignant myeloid hematologic disorders. 21932. All. 18 Years to 60 Years (Adult). NCT01362179. LTDFU. LTDFU. ...
  https://clinicaltrials.gov/ct2/results?term=&recr=&rslt=&type=&cond=&intr=&outc=&lead=&spons=&id=&state1=NA:US:TX&cntry1=&state2=NA:US:TX&cntry2=&state3=&cntry3=&locn=cook+children
*  A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers - Full Text View -...
Hematologic Neoplasms. Neoplasms by Site. Neoplasms. Hematologic Diseases. Rituximab. Antineoplastic Agents. Immunologic ... A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers. The safety and scientific ... in Subjects With Advanced Solid and Hematologic Cancers. ... Hematologic Neoplasms Drug: CC-90002 Drug: Rituximab Phase 1 ...
  https://clinicaltrials.gov/show/NCT02367196
*  Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET...
Hematologic Diseases. Bone Marrow Neoplasms. Hematologic Neoplasms. Neoplasms by Site. Neoplasms. Bone Marrow Diseases. ... To compare hematologic response rates in patients randomized to treatment with Pegylated Interferon Alfa-2a vs Hydroxyurea in ... To compare the hematologic partial response rates on therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea). [ Time Frame: 4 ... Improvement in disease symptoms will be measured by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) ...
  https://clinicaltrials.gov/ct2/show/study/NCT01259856?show_locs=Y
*  Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera - Full...
Hematologic Diseases. Bone Marrow Neoplasms. Hematologic Neoplasms. Neoplasms by Site. Neoplasms. Bone Marrow Diseases. ... Hematologic Response [ Time Frame: From time of first dose (cycle 1 day 1) through end of study (12 mos after last participant ... For patients with ET: To obtain a preliminary estimate of efficacy of imetelstat, as measured by best hematologic response ... Primary objectives are as follows: ET patients - best hematologic response within the first year of therapy and PV patients - ...
  https://clinicaltrials.gov/ct2/show/NCT01243073?term=McDevitt+AND+polycythemia+vera&rank=1
*  Michael Joseph Borowitz, M.D., Ph.D.
Borowitz's research focuses on defining the complexity of hematologic neoplasms. He is particularly interested in the ... Borowitz serves as the Executive Deputy Director in the Department of Pathology and also directs the Division of Hematologic ... His areas of clinical expertise include the diagnosis of hematologic malignancies. Dr. ...
  https://www.hopkinsmedicine.org/profiles/results/directory/profile/0007310/michael-borowitz?dbase=main&spec_disease=Clinical%20Pathology&setsize=10&CLEARPAGECACHE=false&directRef=%2Fdoctors%2Fresults%2Fdirectory%2Fprofile%2F0007310%2Fmichael-borowitz
*  Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral...
Neoplasms, Plasma Cell. Hematologic Neoplasms. Leukemia, Prolymphocytic, T-Cell. Neoplasms by Histologic Type. ... Ages =, 50 years of age with hematologic diseases treatable by allogeneic HCT who refuse a high-dose HCT; transplants must be ... Neoplasms. Leukemia, Myeloid, Acute. Myelodysplastic Syndromes. Preleukemia. Lymphoma, Non-Hodgkin. Leukemia, Lymphoid. ... Ages =, 50 years of age with hematologic diseases treatable by allogeneic HCT who through pre-existing medical conditions or ...
  https://clinicaltrials.gov/ct2/show/NCT01231412?recr=Open&cond=%22Myeloproliferative+Disorders%22&rank=20
*  Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood...
Neoplasms, Plasma Cell. Hematologic Neoplasms. Leukemia, Prolymphocytic, T-Cell. Neoplasms by Histologic Type. Neoplasms. ... Patients with active non-hematologic malignancies (except non-melanoma skin cancers) or those with non-hematologic malignancies ... Ages =, 50 years of age with hematologic diseases treatable by allogeneic HCT who refuse a high-dose HCT; transplants must be ... Ages =, 50 years of age with hematologic diseases treatable by allogeneic HCT who through pre-existing medical conditions or ...
  https://clinicaltrials.gov/ct2/show/NCT01251575?recr=Open&cond=%22Leukemia%2C+Lymphoid%22&rank=19
*  Tumor lysis syndrome - Wikipedia
TLS is most common during cytotoxic treatment of hematologic neoplasms. Risk factors for tumor lysis syndrome depend on several ...
  https://en.wikipedia.org/wiki/Tumor_lysis_syndrome
*  Paraproteinemia - Wikipedia
It is usually due to an underlying immunoproliferative disorder or hematologic neoplasms, especially multiple myeloma. It is ...
  https://en.wikipedia.org/wiki/Paraproteinemia
*  Mycoplasma genitalium - Wikipedia
The protein was identified during investigations on the origin of multiple myeloma, a B-cell hematologic neoplasm. To ...
  https://en.wikipedia.org/wiki/Mycoplasma_genitalium